Literature DB >> 22994513

Clinician's corner: What do we know about safe ascent rates at high altitude?

Andrew M Luks1.   

Abstract

Although pharmacologic strategies are available for decreasing the risk of acute altitude illness, the best means of preventing these problems remains undertaking an adequately slow ascent. Guidelines regarding appropriate ascent rates have been published in various forums, and while these guidelines are generally similar to each other in regards to the recommended ascent rates and use of rest days, there is actually little evidence in the literature supporting the particular recommendations. The purpose of this review is to consider these guidelines and the issue of ascent rates in greater detail. Following a discussion of the evidence regarding ascent rates and acclimatization, the review considers several unanswered questions regarding the current guidelines, including the applicability of the guidelines for all altitude travelers, how best to determine the ascent rate, how to implement rest days, and whether pre-acclimatization strategies can be used to facilitate faster than recommended ascents. Given the current state of evidence, there is no reason to alter the current guidelines, as they likely work for the substantial majority of high altitude travelers. It is individuals traveling to high altitude for the first time for whom they remain most important, while those individuals with substantial prior experience at high altitude may opt for faster or slower ascent rates based on their prior experience. Rest days should remain a part of any ascent profile and should be used following any large gains in elevation rather than simply at specified time intervals. Pre-acclimatization strategies may decrease the risk of acute altitude illness but there is insufficient evidence to suggest they can be used to facilitate faster than recommended ascents. Further research may allow changes in practice in the future but for the time being, adherence to the current recommendations is the prudent approach for the majority of high altitude travelers.

Mesh:

Year:  2012        PMID: 22994513     DOI: 10.1089/ham.2012.1055

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  4 in total

Review 1.  Efficacy of ibuprofen on prevention of high altitude headache: A systematic review and meta-analysis.

Authors:  Juan Xiong; Hui Lu; Rong Wang; Zhengping Jia
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

Review 2.  High-altitude illnesses: Old stories and new insights into the pathophysiology, treatment and prevention.

Authors:  Martin Burtscher; Urs Hefti; Jacqueline Pichler Hefti
Journal:  Sports Med Health Sci       Date:  2021-04-16

3.  Exogenous sphingosine-1-phosphate boosts acclimatization in rats exposed to acute hypobaric hypoxia: assessment of haematological and metabolic effects.

Authors:  Sonam Chawla; Babita Rahar; Mrinalini Singh; Anju Bansal; Deepika Saraswat; Shweta Saxena
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

4.  New metric of hypoxic dose predicts altitude acclimatization status following various ascent profiles.

Authors:  Beth A Beidleman; Charles S Fulco; Allen Cymerman; Janet E Staab; Mark J Buller; Stephen R Muza
Journal:  Physiol Rep       Date:  2019-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.